权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

TAAR1 agonists for nicotine addiction

TAAR1 激动剂治疗尼古丁成瘾

基本信息

批准号：
10561715
负责人：
Jun-Xu Li
金额：
$ 39.55万
依托单位：
STATE UNIVERSITY OF NEW YORK AT BUFFALO
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10561715
关键词：
Abstinence Acute Agonist Amines Attenuated Behavior Behavioral Bupropion Cessation of life Clinical Cocaine Cues Data Development Disease Dopamine Dose Drug Addiction Extinction FDA approved Female Filament Food Health Care Costs Hour Hyperalgesia Incubated Infusion procedures Intravenous Maintenance Mecamylamine Mechanics Mediating Methamphetamine Mission Nicotine Nicotine Dependence Nicotine Withdrawal Nicotinic Agonists Nicotinic Receptors Pharmaceutical Preparations Pharmacotherapy Protocols documentation Psychological reinforcement Public Health Rattus Recording of previous events Regimen Relapse Research Role Schedule Self Administration Sex Differences Smoker Smoking System Testing Therapeutic Tobacco Tobacco Dependence Tobacco smoking behavior Tobacco use Training United States National Institutes of Health Withdrawal Withdrawal Symptom addiction anxiety-like behavior combat cost effective efficacious treatment experience inhibitor long term abstinence male men&apos s group monoamine mortality risk nicotine replacement nicotine seeking behavior nicotine self-administration novel pharmacologic pre-clinical receptor reuptake smoking abstinence smoking cessation success transmission process varenicline

项目摘要

ABSTRACT Tobacco smoking remains a major public health concern globally. Although there are FDA-approved therapeutic options available, they are far from adequate to maintain long-term smoking abstinence in most smokers. Thus, discovering novel efficacious pharmacotherapies to aid in smoking cessation remains an urgent clinical need. Nicotine, the major component in tobacco that is responsible for tobacco addiction, stimulates the mesolimbic dopaminergic system via activating nicotinic acetylcholine receptors (nAChRs). Nicotine replacement therapy and the nAChR partial agonist varenicline have achieved limited clinical success by directly modulating the central nAChRs. Indirect modulation of dopaminergic system by non-dopaminergic mechanism may also be able to modulate the addiction-related effects of nicotine. Trace amine associated receptor 1 (TAAR1) has emerged as a novel target for the development of potential pharmacotherapy to treat drug addiction. In particular, our preliminary data have shown that acute TAAR1 agonist treatment is able to reduce some addiction-related effects of nicotine. The objective of the present application is to systematically assess the therapeutic potential of TAAR1 agonists on nicotine addiction. Three Specific Aims are proposed: Aim 1 will examine the effects of repeated TAAR1 agonists (full agonist RO5166017 and partial agonist RO5263397) treatment on nicotine reinforcement using a short-access (1 hour) nicotine self-administration paradigm; Aim 2 will examine the effects of TAAR1 agonists on the reinstatement and incubation of nicotine- seeking behavior in rats with a long-access (21 hours) nicotine self-administration history; Aim 3 will examine the effects of TAAR1 agonists on nicotine withdrawal in rats with a long-access (21 hours) nicotine self- administration history. Collectively, the proposed studies systematically evaluate the effects of TAAR1 agonists on four critical aspects of nicotine addiction (e.g., reinforcing effects, reinstatement, incubation and withdrawal symptoms), each of which is thought to contribute significantly to nicotine dependence and relapse. Successful execution of the proposed studies will confirm the essential role TAAR1 in mediating nicotine addiction and provide critical preclinical evidence in support of developing TAAR1 agonists are novel pharmacotherapy for smoking cessation.

摘要